Abstract
Introduction
Pancreatectomies increase the risk of postoperative pancreatic fistula (POPF) and pancreatic insufficiency. Pancreatic enucleation preserves pancreatic parenchyma, lowers the risk of pancreatic insufficiency, but may induce specific complications (tumor recurrence or pancreatic fistulization). The aim of this study was to determine the risk factors for POPF following a pancreatic enucleation.
Methods
A retrospective analysis was designed based on data from patients who underwent pancreatic enucleation in five university hospitals (1998–2008). The presence of a pancreatic fistula was determined according to the criteria of the International Study Group of Pancreatic Fistula (Bassi et al. Surgery 138:8–13, 2005).
Results
Fifty-two patients (mean age 52 years) were included. Histological analysis revealed 35 endocrine tumors (68.6 %), 6 mucinous and 2 serous cyst adenomas, 2 metastases of renal cancer, and 8 benign tumors. Nineteen patients (36.5 %) suffered postoperative complications including 14 POPF (27 %). Median postoperative hospital stay was 12.9 days; 9.1 days without POPF versus 29 days with POPF (p < 0.05). Size of the tumor, its location, histological differentiation, and use of somatostatin analogs were not predictors for POPF. We defined the cutoff for POPF at a distance of 2 mm from the main pancreatic duct based on 60 % risk (≤2 mm) versus 19 % (>2 mm) of POPF (p < 0.01). With a mean follow-up of 30.8 months, one patient experienced recurrence of the tumor. No patients exhibited a new onset of diabetes or pancreatic insufficiency.
Conclusion
Enucleation for resection of pancreatic tumors located at less than or equal to two 2 mm from the main pancreatic duct is a risk factor for POPF. Enucleation is a safe and effective treatment for benign or borderline pancreatic tumors.
Similar content being viewed by others
References
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition Surgery 2005; 138:8–13.
Bassi C, Falconi M, Salvia R, Mascetta G, Molinari E, Pederzoli P. Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Dig Surg 2001; 18:453–457.
Falconi M, Mantovani W, Crippa S, Mascetta G, Salvia R, Pederzoli P. Pancreatic insufficiency after different resections for benign tumours. Br J Surg 2008; 95:85–91.
Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004; 18: 947–955.
Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P. Enucleation of pancreatic neoplasms. Br J Surg 2007; 94:1254–1259
Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, Cai LX. Surgical Management of Patients With Insulinomas: Result of 292 Cases in a Single Institution. J Surg Oncol 2011; 103:169–74
Michael W. Müller, MD, Helmut Friess, MD, Jörg Kleeff, MD, Ulf Hinz, MSc, Moritz N. Wente, MD, Daniel Paramythiotis, MD, Pascal O. Berberat, MD, Güralp O. Ceyhan, MD, and Markus W. Büchler, MD An Option to Treat Benign Pancreatic Body Lesions. Ann Surg. 2006; 244: 909–920.
Sauvanet A., Surgical complications of pancreatectomy. J Chir 2008; 145:103–14.
Bassi C. Middle segment pancreatectomy: a useful tool in the management of pancreatic neoplasms? J Gastrointest Surg 2007; 11:726–9.
Molinari E, Bassi C, Salvia R, Butturini G, Crippa S, Talamini G, Falconi M, Pederzoli P. Amylase value in drains after pancreatic resection as predictive factor of postoperative pancreatic fistula: results of a prospective study in 137 patients. Ann Surg. 2007; 246:281–7.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien–Dindo Classification of Surgical Complications: Five-Year Experience Ann Surg: 2009; 250: 187–196
Casadei R, Ricci C, Rega D, D’Ambra M, Pezilli R, Tomassetti P, Campana D, Nori F, Minni F. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas 2010:39:825–8
Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 2009:13:1692–8
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, and al.. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6:17–32.
Goasguen N, Bourrier A, Ponsot P, Bastien L, Lesurtel M, Prat F, Dousset B, Sauvanet A. Endoscopic management of pancreatic fistula after distal pancreatectomy and enucleation. AmJ Surg. 2009; 197:715–20.
Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomised trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997; 226: 632–641.
Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg. 1995; 221:635–648.
Fendrich V, Merz MK, Waldmann J, Langer P, HeverHagen AE, Dietzel K, Bartsch DK. Neuroendocrine pancreatic tumors are risk factors for pancreatic fistula after pancreatic surgery. Dog Surg 2011; 28:263–9.
Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg 2006 ;93:264–275.
Fernández-Cruz L, Blanco L, Cosa R, Rendón H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg. 2008; 32:904–17.
Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005; 137:597–605
Isla A, Arbuckle JD, Kekis PB, Lim A, Jackson JE, Todd JF, Lynn J. Laparoscopic management of insulinomas. Br J Surg. 2009; 96:185–90.
Ramos-De la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreat Surg. 2006; 13:190–3.
Connor S, Alexakis N, Garden OJ, Leandros E, Bramis J, Wigmore SJ. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg. 2005; 92:1059–67.
Zeng Q, Zhang Q, Han S, Yu Z, Zheng M, Zhou M, Bai J, Jin R. Efficacity of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas. 2008; 36:18–25.
Conflict of Interest
The authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The institution from which the work originated is Clinique de Chirurgie Digestive et Endocrinienne, IMAD, University Hospital, Nantes, France.
Rights and permissions
About this article
Cite this article
Brient, C., Regenet, N., Sulpice, L. et al. Risk Factors for Postoperative Pancreatic Fistulization Subsequent to Enucleation. J Gastrointest Surg 16, 1883–1887 (2012). https://doi.org/10.1007/s11605-012-1971-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-012-1971-x